The hazards of dual renin-angiotensin blockade in chronic kidney disease

Archives of Internal Medicine

Volumn 169, Issue 11, 2009, Pages 1015-1018

  Ku, Elaine ^b   Park, Jeanie ^b   Vidhun, Jay ^b   Campese, Vito ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FAILURE; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; NOTE; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY DISEASES; PROTEINURIA; RENIN-ANGIOTENSIN SYSTEM;

EID: 67249125166     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.128     Document Type: Note

References (48)

1. USRDS. 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: US Renal Data System; 2008.
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047. (Pubitemid 350074801)
3. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004.AmJ Kidney Dis. 2008; 51(4)(suppl 2):S30-S37.
4. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol. 2007; 18(10):2644-2648. (Pubitemid 47531190)
5. Owen WF Jr. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement. J Am Soc Nephrol. 2003; 14(7)(suppl 2):S76-S80. (Pubitemid 36750497)
6. Toto R, Palmer BF. Rationale for combination angiotensin receptor blocker and angiotensinconverting enzyme inhibitor treatment and endorgan protection in patients with chronic kidney disease. Am J Nephrol. 2008;28(3):372-380.
7. Werner C, Baumhakel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol. 2008;97(7):418-431.
8. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005;(99):S57-S65. (Pubitemid 44324688)
9. Luño J, Barrio V, Goicoechea MA, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int Suppl. 2002;(82):S47-S52. (Pubitemid 35356996)
10. Ferrari P. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Nephrology (Carlton). 2007;12(1):81-89. (Pubitemid 46246558)
11. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol. 2002;13(4): 1100-1108.
12. Masri G, Bledsoe K, Palacio C. Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination at an urban medical center. MedGenMed. 2007;9(4):40. (Pubitemid 350143072)
13. Basile JN, Lackland DT, Basile JM, Riehle JE, Egan BM. A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004;6(1):18-25.
14. Maschio G, Alberti D, Janin G, et al; Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency N Engl J Med. 1996;334(15):939-945. (Pubitemid 26114159)
15. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116(2):288-296. (Pubitemid 43228342)
16. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008;3(suppl 1):S3-S10.
17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; Collaborative Study Group. The effect of angiotensinconverting-enzymeinhibitionondiabeticnephropathy. N Engl J Med. 1993;329(20):1456-1462.
18. Perico N, Codreanu I, Schieppati A, Remuzzi G. Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago? Kidney Int Suppl. 2005;(98):S21-S24.
19. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol. 1990;15(2):276-282. (Pubitemid 20040586)
20. Juillerat L, Nussberger J, Menard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990; 16(5):564-572. (Pubitemid 20368346)
21. Urata H, Nishimura H, Ganten D. Chymasedependent angiotensin II forming systems in humans. Am J Hypertens. 1996;9(3):277-284. (Pubitemid 26122448)
22. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67(3): 799-812. (Pubitemid 41623305)
23. Azizi M, Wuerzner G. Rationale for combining blockers of the renin-angiotensin system. Semin Nephrol. 2007;27(5):544-554. (Pubitemid 47381469)
24. Danilczyk U, Penninger JM. Angiotensinconverting enzyme II in the heart and the kidney. Circ Res. 2006;98(4):463-471.
25. Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68(5):2189-2196.
26. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-convertingenzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361(9352):117-124. (Pubitemid 36092015)
27. Krüger B, Boger C, Stubanus M, Fischereder M, Kramer BK. The COOPERATE trial. Lancet. 2003; 361(9362):1054.
28. Nakao N, Kimura G. Submaximal dose of trandolapril in the COOPERATE trial? Kidney Int. 2003; 64(5):1921.
29. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63(5):1874-1880. (Pubitemid 36513336)
30. Presne C, Mansour J, Makdassi R, Choukroun G, Fournier A. The COOPERATE trial. Lancet. 2003; 361(9362):1054.
31. Esnault VL, Ekhlas A, Delcroix C, Moutel MG, Nguyen JM. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. JAmSoc Nephrol. 2005;16(2):474-481. (Pubitemid 41725144)
32. Halbekath J, Schenk S. The COOPERATE trial. Lancet. 2003;361(9362):1055.
33. Kunz R, Wolbers M, Glass T, Mann JF. The COOPERATEtrial: a letter of concern. Lancet. 2008; 371(9624):1575-1576.
34. Linas SL. Are two better than one? angiotensinconverting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease. Clin J Am Soc Nephrol. 2008;3(suppl 1):S17-S23.
35. Ghali JK, Tam SW, Ferdinand KC, et al; A-HeFT Investigators. Effects of ACE inhibitors or betablockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. Am J Cardiovasc Drugs. 2007;7(5):373-380. (Pubitemid 47624541)
36. Norris KC, Tareen N, Martins D, Vaziri ND. Implications of ethnicity for the treatment of hypertensive kidney disease, with an emphasis on African Americans. Nat Clin Pract Nephrol. 2008;4(10): 538-549.
37. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431.
38. Tylicki L, Rutkowski P, Renke M, et al. Triple pharmacological blockade of the renin-angiotensinaldosterone system in nondiabetic CKD: an open label crossover randomized controlled trial. Am J Kidney Dis. 2008;(3):486-493 52.
39. Kunz R, Friedrich C, Wolbers M, Mann JF. Metaanalysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30-48. (Pubitemid 351688350)
40. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440-1444.
41. Sengul AM, Altuntas Y, Kurklu A, Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract. 2006; 71(2):210-219. (Pubitemid 43112114)
42. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005; 68(3):1190-1198. (Pubitemid 43246436)
43. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF; European Group for the Investigation of Valsartan in Chronic Renal Disease. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. J Hypertens. 2000;18(1):89-95.
44. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48(1):8-20. (Pubitemid 43912958)
45. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285(4):437-443. (Pubitemid 32097262)
46. Mann JF, Schmieder RE, McQueen M, et al; ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.
47. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet. 2008;372(9638): 511-512.
48. McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-771.